Sanofi (NASDAQ:SNY) has executed the first tranche of its €5 billion stock buyback program. A first tranche of this program was announced on February 3, 2025, and executed on February 5, 2025, for an ...

Sanofi (SNY), a French pharmaceutical and healthcare company, Friday announced that it is executing the second tranche of its share ...

Execution of a share buyback agreement for up to €2 billion Paris, February 7, 2025. On January 30, 2025 ( Sanofi ...

On February 6, 2025, Sanofi has entered into a mandate with an investment service provider for the second tranche of this program. Under the terms of this mandate, Sanofi will repurchase its own ...

CFRA analysts increased their price target on shares of Sanofi (SAN:FP) (NASDAQ: NASDAQ:SNY) to EUR6.50, up from the previous EUR5.00, while keeping a Buy rating on the stock. Currently trading at $54 ...

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

We recently compiled a list of the 10 Best Foreign Stocks With Dividends For Passive Income. In this article, we are going to ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

Shares of Swedish Orphan Biovitrum AB (STO:SOBI) fell 3% as the company's fourth-quarter earnings report revealed mixed results. While overall Q4 revenue met consensus expectations, sales of its key ...

Regeneron beat Q4 estimates with $12.07 EPS and $3.79B in sales. The company announced a dividend, a $3 billion buyback, and continued R&D investments.

EYLEA HD is anticipated to gain traction with the launch of a prefilled syringe in mid-2025 and label expansions for macular edema and extended dosing intervals. Management believes these developments ...

The Senate Finance Committee advances the nomination of Robert F. Kennedy Jr. for HHS Secretary amid a party-line vote. Read ...